PWPS
PTGX icon

Pinnacle Wealth Planning Services’s Protagonist Therapeutics PTGX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Sell
3,129
-3
-0.1% -$313 0.04% 288
2026
Q1 		$330K Buy
3,132
+268
+9% +$23.7K 0.03% 309
2025
Q4 		$250K Buy
+2,864
New +$234K 0.03% 391

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pinnacle Wealth Planning Services's PTGX Position: Q2 2026 in Review

Pinnacle Wealth Planning Services reduced its Protagonist Therapeutics (PTGX) stake by 0.1% in Q2 2026, selling an estimated $313 and leaving 3,129 shares worth $384K. The position accounts for 0.04% of the portfolio, ranked #288.

Pinnacle Wealth Planning Services first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Pinnacle Wealth Planning Services held 3,129 shares of Protagonist Therapeutics worth $384K as of Q2 2026.
  • Pinnacle Wealth Planning Services sold 3 Protagonist Therapeutics shares in Q2 2026, an estimated $313.
  • Protagonist Therapeutics made up 0.04% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #288 holding.
  • Pinnacle Wealth Planning Services first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.